We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Research peptide — not a dietary supplement
AOD-9604 is a research compound, not a regulated dietary supplement. It is typically administered by injection and sold “for research use only.” The evidence below is largely preclinical (animal and in-vitro) or early-stage, so no evidence score is assigned. This page is provided for transparency and education — it is not a recommendation to use. Consult a qualified healthcare provider, and be aware that purity, dosing, and legal status vary by jurisdiction.
What the evidence says
Most AOD-9604 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1978–2026.
Based on 8 studies
Confidence
LowBy outcome
The current evidence for AOD-9604 is insufficient to assign an evidence score, based on 8 indexed studies. A synthetic fragment of human growth hormone (hGH 176-191) that was developed as an anti-obesity drug — and FAILED. Honest appraisal: its clinical development for obesity did not pan out; the human trials did not produce meaningful weight loss beyond placebo, and the program was discontinued as an obesity drug. It is NOT an approved medicine or dietary supplement: it is now sold grey-market 'for research use only' for fat loss, a use that the failed trials never supported. The supportive data are preclinical (lipolysis in obese mice/rats and cartilage repair in a rabbit knee model), and it is a WADA-banned substance. Representative study: PMID 11673763.
The commonly studied dose of AOD-9604 is No validated human dose exists for any benefit. AOD-9604's human obesity trials did not establish an effective weight-loss dose because they did not show meaningful weight loss. Anecdotal grey-market injectable protocols circulated online use roughly 300 mcg/day subcutaneously, but these figures have no clinical basis, no validated efficacy, and should not be read as a recommendation.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 8 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
AOD-9604 (Anti-Obesity Drug 9604, hGH fragment 176-191)
A synthetic fragment of human growth hormone (hGH 176-191) that was developed as an anti-obesity drug — and FAILED. Honest appraisal: its clinical development for obesity did not pan out; the human trials did not produce meaningful weight loss beyond placebo, and the program was discontinued as an obesity drug. It is NOT an approved medicine or dietary supplement: it is now sold grey-market 'for research use only' for fat loss, a use that the failed trials never supported. The supportive data are preclinical (lipolysis in obese mice/rats and cartilage repair in a rabbit knee model), and it is a WADA-banned substance.
A grey-market research peptide whose anti-obesity development reached phase II and FAILED to beat placebo; every supporting efficacy finding is animal-only, and human safety and the marketed fat-loss benefit are unproven.
AOD-9604 ('Anti-Obesity Drug 9604') is a synthetic peptide corresponding to the C-terminal lipolytic domain of human growth hormone (amino acids 176-191, with an added N-terminal tyrosine).
It was designed to reproduce the fat-burning (lipolytic) actions of growth hormone without GH's diabetogenic and growth-promoting side effects, and was advanced by Metabolic Pharmaceuticals as an oral anti-obesity drug.
The honest development story is one of failure: preclinical studies in obese mice and Zucker rats showed real reductions in body-weight gain, increased fat oxidation and increased lipolysis (with, importantly, no impairment of insulin sensitivity — unlike intact GH).
But when the compound moved into human obesity trials in the 2000s, it did not deliver.
The clinical program (which reached phase II) did not demonstrate meaningful weight loss over placebo, and AOD-9604's development as an obesity therapeutic was abandoned — it was never approved by any regulator for obesity or any other indication.
(Note: the pivotal human obesity trial results were reported through company/conference channels and are not indexed as a standalone PubMed paper; the PubMed record of the program is captured by development-stage reviews and clinical-trials bibliographies, which we cite honestly rather than fabricating a trial PMID.) Today AOD-9604 survives almost entirely as a grey-market injectable (and sometimes oral) 'research peptide' promoted for fat loss — precisely the use its own clinical trials failed to validate.
The only newer human-relevant signal is a preclinical one: an intra-articular rabbit knee study suggesting cartilage-repair potential in osteoarthritis, which has spurred interest in joint applications but remains animal-stage.
AOD-9604 is on the World Anti-Doping Agency prohibited list, so it is detectable and banned in sport.
Overall: the marketed fat-loss benefit is unproven (indeed, contradicted by the failed clinical development), the supportive efficacy data are preclinical, human safety beyond short trials is unknown, and product sourcing is unregulated. Evidence is best described as failed/emerging, not established.
AOD-9604 reproduces the C-terminal (176-191) lipolytic domain of human growth hormone. In obese rodents it increased adipose-tissue lipolytic activity, raised plasma glycerol (an index of fat breakdown) and increased fat oxidation. Notably it did NOT bind or compete for the hGH receptor and did not induce cell proliferation — so it is thought to act through a receptor-independent, GH-fragment-specific route rather than classical GH signalling.
In obese mice AOD-9604 (like intact hGH) raised the repressed expression of beta-3 adrenergic receptor RNA — the major lipolytic receptor in fat cells — toward lean levels. However, in beta-3-knockout mice chronic AOD-9604 failed to reduce body weight, indicating its weight-lowering effect depends on an intact beta-adrenergic system even though it does not act directly through the beta-3 itself.
How AOD-9604 works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
No validated human dose exists for any benefit. AOD-9604's human obesity trials did not establish an effective weight-loss dose because they did not show meaningful weight loss. Anecdotal grey-market injectable protocols circulated online use roughly 300 mcg/day subcutaneously, but these figures have no clinical basis, no validated efficacy, and should not be read as a recommendation.
Can be taken without food
| Form | Type |
|---|---|
| 💊None — no form has validated human efficacy or an approved standard | Recommended |
AOD-9604 is a research chemical whose obesity development failed; it is not an approved drug or dietary supplement. There is no quality-controlled, regulator-sanctioned product.
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: No evidence-based timing exists. Grey-market fasted-morning injection protocols are anecdotal and unvalidated.
Dose-response data unavailable. The current published research for AOD-9604 does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
AOD-9604's reason for existing was obesity treatment, and that is exactly where it failed: its clinical development did not show meaningful weight loss over placebo, and the program was discontinued. Every weight-loss claim made for the grey-market product is contradicted by its own failed trials.
In obese mice and Zucker rats AOD-9604 reduced body-weight gain, increased adipose lipolytic activity, raised plasma glycerol and increased fat oxidation. These are genuine preclinical effects — but they did not translate into clinical weight loss in humans.
Unlike intact growth hormone, AOD-9604 did not cause hyperglycaemia or worsen insulin sensitivity in rodents. A favourable preclinical signal, not a demonstrated human benefit.
Intra-articular AOD-9604 enhanced cartilage regeneration in a collagenase-induced rabbit knee-osteoarthritis model, and worked better combined with hyaluronic acid. Entirely preclinical; no human joint data.
AOD-9604 is on the World Anti-Doping Agency prohibited list and is detectable in urine/serum. Use by tested athletes constitutes an anti-doping rule violation.
Avoid — never studied in pregnancy or lactation.
Avoid — AOD-9604 is on the WADA prohibited list and is detectable in doping controls.
Use only under medical supervision — human glucose effects are not adequately characterised.
AOD-9604 was designed to avoid GH's diabetogenic effect and did not impair glucose handling in rodents, but its effect on glucose control in people on antidiabetic drugs has never been characterised in adequately powered human trials. Treat any combination as unstudied and monitor.
Tip: There is no verified safe product; risk stems from unregulated 'research use only' sourcing rather than the peptide itself.
Tip: Human safety beyond short clinical trials is unknown; absence of reported harm is not evidence of safety.
The best time to take AOD-9604 is in the morning. It can be taken on an empty stomach. There is no evidence-based dosing schedule because the human program failed to define an effective regimen.
AOD-9604 should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are injection-related risks (infection, abscess, contamination from non-sterile grey-market product), unknown long-term effects. Use caution if any of these apply to you: Pregnancy and breastfeeding — never studied; avoid entirely; Drug-tested athletes — AOD-9604 is a WADA-prohibited substance; Any use expecting a regulated, quality-controlled medicine — AOD-9604 is a research chemical whose development failed, not an approved drug or supplement.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Unlike intact growth hormone, AOD-9604 did not induce hyperglycaemia, did not reduce insulin secretion, and did not worsen insulin sensitivity in rodent studies (euglycaemic-clamp data in Zucker rats). This separation of fat-burning from glucose impairment was the original therapeutic rationale — but it was demonstrated in animals, and the clinical weight-loss benefit it was meant to enable did not materialise in humans.